Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model

References

• Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv. 2001;438:1–12. doi:10.1007/s004280000338. PMID:11213830
   PubMed Web of Science ®Google Scholar
• Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Path. 2006;59:557–563. doi:10.1136/jcp.2005.031112. PMID:16731599
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580. doi:10.1126/science.279.5350.577. PMID:9438854
   PubMed Web of Science ®Google Scholar
• Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Path. 2009;62:613–616. doi:10.1136/jcp.2009.064550. PMID:19561230
   PubMed Web of Science ®Google Scholar
• Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3–14. doi:10.1007/s10120-015-0526-8. PMID:26276366
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1–41. doi:10.6004/jnccn.2010.0116. PMID:20457867
   PubMed Web of Science ®Google Scholar
• Habeck M. FDA licences imatinib mesylate for CML. Lancet Oncol. 2002;3:6. doi:10.1016/S1470-2045(01)00608-8. PMID:11905608
   PubMed Web of Science ®Google Scholar
• Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–3038. PMID:12374669
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367–1373. doi:10.1158/1078-0432.CCR-06-2328. PMID:17332278
   PubMed Web of Science ®Google Scholar
• FDA approves regorafenib (Stivarga) for GIST. Oncol (Williston Park, NY). 2013;27:164.
   Google Scholar
• Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5 Suppl 2:S1–29. PMID:17624289
   PubMedGoogle Scholar
• Hiroshima Y, Zhang Y, Murakami T, et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograph (PDOX) and cell line mouse models. Oncotarget. 2014;5:12346–12357.
   PubMedGoogle Scholar
• Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA. 1992;89:5645–5649. doi:10.1073/pnas.89.12.5645. PMID:1608975
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Maawy A, Zhang Y, et al. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19–9-conjugated fluorophore. PLoS One. 2014;9:e114310. doi:10.1371/journal.pone.0114310. PMID:25463150
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Maawy AA, Katz MH, et al. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. J Surg Oncol. 2015;111:311–315. doi:10.1002/jso.23816. PMID:25394368
   PubMed Web of Science ®Google Scholar
• Fu X, Le P, Hoffma RM. A metastatic-orthotopic transplant nude-mouse model of human patient breast cancer. Anticancer Res. 1993;13:901–904. PMID:8352558
   PubMed Web of Science ®Google Scholar
• Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993;13:283–286. PMID:8517640
   PubMed Web of Science ®Google Scholar
• Wang X, Fu X, Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer. 1992;51:992–995. doi:10.1002/ijc.2910510626. PMID:1639545
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Zhang Y, Zhang N, et al. Establishment of a patient-derived orthotopic xenograph (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One. 2015;10:e0117417. doi:10.1371/journal.pone.0117417. PMID:25689852
   PubMed Web of Science ®Google Scholar
• Fu X, Besterman JM, Monosov A, et al. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA. 1991;88:9345–9349. doi:10.1073/pnas.88.20.9345. PMID:1924398
   PubMed Web of Science ®Google Scholar
• Metildi CA, Kaushal S, Luiken GA, et al. Fluorescently-labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg Oncol. 2014;109:451–458. doi:10.1002/jso.23507. PMID:24249594
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Maawy A, Metildi CA, et al. Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. J Laparoendosc Adv Surg Tech A. 2014;24:241–247. doi:10.1089/lap.2013.0418. PMID:24494971
   PubMed Web of Science ®Google Scholar
• Furukawa T, Kubota T, Watanabe M, et al. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer. 1993;53:608–612. doi:10.1002/ijc.2910530414. PMID:8436434
   PubMed Web of Science ®Google Scholar
• Murakami T, DeLong J, Eilber FC, et al. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model. Oncotarget. 2016;7:12783–12790.
   PubMedGoogle Scholar
• Hiroshima Y, Zhao M, Zhang Y, et al. Tumor-targeting Salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice. PLoS One. 2015;10:e0134324. doi:10.1371/journal.pone.0134324. PMID:26237416
   PubMed Web of Science ®Google Scholar
• Kiyuna T, Murakami T, Tome Y, et al. High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. Oncotarget. 2016;7:33046–33054. doi:10.18632/oncotarget.8848. PMID:27105519
   PubMedGoogle Scholar
• Murakami T, Singh AS, Kiyuna T, et al. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2016;7:47556–47564.
   PubMed Web of Science ®Google Scholar
• Hiroshima Y, Zhang Y, Zhang N, et al. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. Anticancer Res. 2015;35:697–701. PMID:25667448
   PubMed Web of Science ®Google Scholar
• Igarashi K, Murakami T, Kawaguchi K, et al A patient-derived orthotopic xenograft (PDOX) mouse model of an cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. Oncotarget. 2017;8:62111–62119. PMID:28977930
   PubMedGoogle Scholar
• Igarashi K, Kawaguchi K, Kiyuna T, et al. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017;8:75874–75880. PMID:29100276
   PubMedGoogle Scholar
• Igarashi K, Kawaguchi K, Murakami T, et al. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Cell Cycle. 2017;16:1164–1170. doi:10.1080/15384101.2017.1317417. PMID:28494180
   PubMed Web of Science ®Google Scholar
• Murakami T, Kiyuna T, Kawaguchi K, et al. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle. 2017;16:1046–1052. doi:10.1080/15384101.2017.1304340. PMID:28296559
   PubMed Web of Science ®Google Scholar
• Igarashi K, Kawaguchi K, Murakami T, et al. High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Cell Biochem. 2017;118:2739–3743. doi:10.1002/jcb.25923. PMID:28176365
   PubMed Web of Science ®Google Scholar
• Kiyuna T, Murakami T, Tome Y, et al. Analysis of stroma labeling during multiple passage of a sarcoma imageable patient-derived orthotopic xenograft (iPDOX) in red fluorescent protein transgenic nude mice. J Cell Biochem. 2017;118:3367–3371. doi:10.1002/jcb.25991. PMID:28300287
   PubMed Web of Science ®Google Scholar
• Igarashi K, Murakami T, Kawaguchi K, et al. A patient-derived orthotopic xenograft (PDOX) mouse model of an cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. Oncotarget. 2017;8:62111–62119. PMID:28977930
   PubMedGoogle Scholar
• Igarashi K, Kawaguchi K, Kiyuna T, et al. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017;8:75874–75880. PMID:29100276
   PubMedGoogle Scholar
• Igarashi K, Kawaguchi K, Murakami T, et al. A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX). Oncotarget. 2017;8:63353–63359. PMID:28968995
   PubMedGoogle Scholar
• Miyake K, Murakami T, Kiyuna T, et al. The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. Oncotarget. 2017;8:103129–103136. PMID:29262551
   PubMedGoogle Scholar
• Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E mutated melanoma is regressed by MEK targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;7:71737–71743. PMID:27690220
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Igarashi K, Murakami T, et al. Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600 mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget. 2016;7:85929–85936.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Igarashi K, Murakami T, et al. Tumor-targeting Salmonella typhimurium A1-R sensitizes melanoma with a BRAF-V600E mutation to vemurafenib in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Cell Biochem. 2017;118:2314–2319. doi:10.1002/jcb.25886. PMID:28106277
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Igarashi K, Li S, et al. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma growth in a patient-derived orthotopic xenograft. Oncotarget. 2017;8:85516–85525. PMID:29156737
   PubMedGoogle Scholar
• Yamamoto M, Zhao M, Hiroshima Y, et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. PLoS One. 2016;11:e0160882. doi:10.1371/journal.pone.0160882. PMID:27500926
   PubMed Web of Science ®Google Scholar
• FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncol (Williston Park, NY). 2012;26:896.
   Google Scholar
• Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794–1799. doi:10.1093/annonc/mdw228. PMID:27371698
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today. 2003;8:1104–1107. doi:10.1016/S1359-6446(03)02806-X. PMID:14678733
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Teratogens as anti-cancer drugs. Cell Cycle. 2005;4:1518–1521. doi:10.4161/cc.4.11.2208. PMID:16258270
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia. 2001;15:936–941.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006;20:385–391. doi:10.1038/sj.leu.2404075. PMID:16357832
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, et al. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011;2:222–233. doi:10.18632/oncotarget.248. PMID:21447859
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer. 2003;89:1147–1151. doi:10.1038/sj.bjc.6601256. PMID:14520435
   PubMed Web of Science ®Google Scholar